SCIENTIFIC PROGRAMME
Draft Preliminary Programme
Thursday, april 25
9:30-11:30 - Educational course on psoriasis
Chair: Esteban Dauden (Spain)
1. Genetics/pathogenesis - Paola di Meglio (UK)
2. Comorbidities - Tiago Torres (Portugal)
3. Topical therapy - Rolland Gyulai (Hungary)
4. Non-biologic systemic therapy - Paola Cardenas (Colombia)
5. Biologic systemic therapy - David Moreno (Spain)
11:30-12:30 Satellite Symposia
12.30-14.00 Welcome reception
14.00-14:10 – Congress Opening:
Fondation René Touraine Welcome and update on SPIN
14:10-16.00 – Plenary 1: Genetics and pathogenesis in psoriasis and atopic dermatitis
Chairs: Pedro Herranz (Spain) & Georg Stingl (Austria)
1. Genetics in psoriasis and atopic dermatitis - Jonathan Barker (UK)
2. New developments in immunopathogenesis of psoriasis- Antonio Costanzo (Italy)
3. Genetics and immunopathogenesis of pustular variants of psoriasis - Hervé Bachelez (France)
4. Autoimmunity vs autoinflammation in psoriasis - Spearker TBC
5. Pathogenesis in psoriasis and atopic dermatitis. Similarities and differences - Emma Guttman-Yassky (US)
16.00-16.30 – Break & Discussed E-Posters
16.30-18.00 – Focus Session 1: Epidemiology and registries
Chairs: Paula Seijo-Dávila (Spain) & Luigi Naldi (Italy)
1. Registries in dermatology: strengths and learning points - Phyllis Spuls (Netherlands)
2. Epidemiology of major inflammatory skin diseases anno 2019 - Luigi Naldi (Italy)
3. Epidemiology of major inflammatory skin diseases in emerging countries - Alur Kumar (India)
4. Comorbidity occurrence in major inflammatory skin diseases - Alexander Egeberg (Denmark)
FREE COMMUNICATIONS:
P001
SAFETY EVENTS OCCURRING AMONG PATIENTS EXPOSED TO IXEKIZUMAB IN THE CORRONA PSORIASIS REGISTRY
E.Grace *, B.Zhu , W.Malley , J.O’Brien , R.Magner , N.Agada , G.Gallo , T.Bhutani (Indianapolis, United States)
P002
NUMBER NEEDED TO TREAT AND COST PER RESPONDER FOR FLEXIBLE ADALIMUMAB DOSING IN THE TREATMENT OF PSORIASIS IN PATIENTS WITH SUBOPTIMAL RESPONSE TO 40MG EVERY OTHER WEEK DOSING
L. J.Savage *, V.Garcia-Horton , J.Li , L.Yin , K. A.Betts , B.Calimlim (Leeds, United Kingdom)
P003
RESPONSE TO ADALIMUMAB IN PATIENTS WITH PLAQUE PSORIASIS BY ASSOCIATED MANIFESTATIONS: ANALYSES FROM THE BRITISH ASSOCIATION OF DERMATOLOGISTS BIOLOGICS AND IMMUNOMODULATORS REGISTER
L. J.Savage *, D.Dasgupta , O.Reyes-Servin , B.Calimlim (Leeds, United Kingdom)
16.30-18.00 – Focus Session 2: Advances in target-oriented therapy
Chairs: Romana Ceovic (Croatia) & Skaidra Valiukeviciene (Lithuania)
1. Atopic dermatitis - Spearker TBC
2. Psoriasis - Alexander Nast (Germany)
3. Psoriatic arthritis - Wolf-Henning Boehncke (Switzerland)
4. Biomarkers in psoriasis and atopic dermatitis - Spearker TBC
FREE COMMUNICATIONS:
P004
GUSELKUMAB DEMONSTRATES SUPERIOR LONG-TERM RESPONSES COMPARED WITH SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE ECLIPSE TRIAL
K.Reich *, A.Armstrong , A.Blauvelt , S.Li , M.-C.Hsu , S.Flavin , B.Randazzo , R.Langley (Hamburg, Germany)
P005
LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: RESULTS FROM MORE THAN 17000 PATIENT-YEARS OF EXPOSURE
C. E.Griffiths *, M. G.Lebwohl , A.Blauvelt , K.Reich , M.Gooderham , T.Terui , N.Agada , W.Xu , G.Gallo (Manchester, United Kingdom)
P006
IMMEDIATE ONSET OF ACTION OF BRODALUMAB COMPARED WITH USTEKINUMAB: RESULTS FROM THE PHASE 3 AMAGINE-2 AND -3 STUDIES
S.Philipp *, J.Hansen , V.Schultz Nielsen , A.Chiricozzi (Berlin, Germany)
Friday, April 26
08.30-10.00 – Focus Session 3: Autoinflammation and autoimmunity
Chairs: Lara Ferrandiz (Spain) & Richard Warren (UK)
1. Autoimmunity in psoriasis - Jörg Prinz (Germany)
2. Life imaging of cutaneous immune-responses - Kenji Kabashima (Japan)
3. Microbiome in major inflammatory skin diseases - Chris Callewaert (Belgium)
4. Autoinflammation and autoimmunity in psoriasis vs hidradenitis suppurativa - Antonio Martorell (Spain)
FREE COMMUNICATIONS:
P007
THE ROLE OF NEUROIMMUNE INTERACTION IN PATHOPHYSIOLOGY OF GRANULOMATOUS ROSACEA
E.Hong *, K.Kim (Gyeonggi-do, Korea, Republic Of)
P008
ROLE OF KERATIN 24 IN HUMAN EPIDERMAL KERATINOCYTES
M.Zheng *, M.Min , X.Man (Hangzhou, China)
08.30-10.00 – Focus Session 4: Beyond the skin
Chairs: Paolo Gisondi (Italy) & Jacob Thyssen (Denmark)
1. Psychological and psychiatric comorbidities in major inflammatory skin diseases - Marta Garcia-Bustinduy (Spain)
2. Hepatic and musculoskeletal disease in psoriasis - Paolo Gisondi (Italy)
3. Cardiovascular comorbidities in major inflammatory skin diseases - Stefano Piaserico (Italy)
4. Auto-immune diseases in atopic dermatitis - Jacob Thyssen (Denmark)
FREE COMMUNICATIONS:
P009
THERAPEUTIC PATIENT EDUCATION AND SELF-MANAGEMENT SUPPORT FOR PATIENTS WITH PSORIASIS – A LIVING SYSTEMATIC REVIEW AND META-ANALYSIS
C.Dressler , M.Zidane , L.Grine , P.Galdas , J.Lambert , A.Nast * (Berlin, Germany)
P010
DEVELOPMENT OF A PATIENT CHARTER FOR PEOPLE LIVING WITH CONDITIONS, DISEASES OR TRAUMAS INVOLVING THE SKIN
A.Sivanand , K.Andrews-Clay * (Ottawa, Canada)
10.30-12.30 – Plenary 2: Novelties in therapeutics
Chairs: Pablo de la Cueva (Spain) & Thomas Luger (Germany)
1. Anti TNF and small molecules in psoriasis - Sandra Philipp (Germany)
2. Anti IL17 in psoriasis - Carle Paul (France)
3. Anti p40/anti p19 in psoriasis - Kristian Reich (Germany)
4. New molecules in atopic dermatitis - Diamant Thaçi (Germany)
5. Which drug for which patient ? - Emilie Sbidian (France)
6. Latest trials on the effect of biotherapy on cardiovascular disease in psoriasis - Nehal Mehta (US)
12.30-14.00 Lunch break / Satellite Symposia
14.00-15.30 Focus Session 5 - Topical treatments and physical modalities of treatment
Chairs: José Manuel Carrascosa (Spain) & Lajos Kemeny (Hungary)
1. Topical therapy in psoriasis and atopic dermatitis - José Manuel Carrascosa (Spain)
2. UVB in psoriasis and atopic dermatitis - Piergiacomo Calzavara (Italy)
3. Innovative phototherapeutic approaches in psoriasis and atopic dermatitis - Lajos Kemeny (Hungary)
4. Physical treatment modalities in hidradenitis suppurativa - Speaker TBC
14.00-15.30 – Focus Session 6 – Advances and latest insights in non biologic systemic therapeutic agents in psoriasis and atopic dermatitis
Chairs: Raquel Rivera (Spain) & Martine Bagot (France)
1. Fumarates / Vitamin A Derivatives - Peter van de Kerkhof (Netherlands)
2. CsA / MMF /Azathioprine - César Gonzalez (Colombia)
3. MTX - Rolland Gyulai (Hungary)
4. Apremilast and -inibs - Richard Langley (Canada)
FREE COMMUNICATIONS:
P011
UPADACITINIB IMPROVED PATIENT-REPORTED PRURITUS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL
C.-H.Hong *, T.Wu , B.Calimlim , H.Teixeira , M.de Bruin-Weller (Surrey, Canada)
P012
DRUG SURVIVAL OF FUMARIC ACID ESTERS (FAE) FOR MODERATE-TO-SEVERE PSORIASIS IN A GERMAN PSORIASIS REGISTRY: PSOBEST
K.Reich , M. A.Radtke , C.Sorbe *, M.Augustin (Hamburg, Germany)
P013
INTERIM ANALYSIS OF SKILL NON-INTERVENTIONAL STUDY: DIMETHYLFUMARATE IN LONG-TERM TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ROUTINE PRACTICE – CHARACTERISATION OF PATIENT POPULATION IN COMPARISON WITH PSOBEST AND PSOHEALTH
M.Augustin , C.Sorbe *, A.Kirsch , S.Diemert (Hamburg, Germany)
15.30-18.00: SPIN Forum
Chairs: Louis Dubertret (France) & Chih-ho Hong (Canada)
1. Limitations on access to conventional/biologic therapy around the world - Maria Lorna Frez (Philippines), Nejib Doss (Tunisia), Nélida Raimondo (Argentina)
2. Screening and follow up for conventional/biologic therapy - Carlos Muñoz (Spain), Emad Elgamal (Egypt)
3. Infections in patients under immunosuppressive drugs: learning from difference - Marta Ferran (Spain), Fernando Valenzuela (Chile), Ibrahim Almukahal (Libya)
Discussion
15.30-18.00: How do I manage?
Chairs: Luis Puig (Spain), Peter Van de Kerkhof (Netherlands) & AJ Kanwar (India)
1. Pregnancy - Juan Raul Castro (Colombia)
2. Childhood psoriasis - Marieke Seyger (Netherlands)
3. Chronic hepatic disease - Eva Vilarassa (Spain)
4. Chronic infections - Fatimata Ly (Senegal)
5. Nail psoriasis - Bertrand Richert (Belgium)
6. Recalcitrant atopic dermatitis - Esther Serra (Spain)
Saturday, April 27
08.30-10.00 – Focus Session 7: Treatment goals/guidelines in major inflammatory skin diseases
Chair: Luis Puig (Spain)
1. Treatment goals in psoriasis - Ulrich Mrowietz (Germany)
2. Guideline variability across countries - Jashin Wu (US)
3. Drug survival - Elke de Jong (Netherlands)
4. Treatment outcomes and goals in atopic dermatitis - Speaker TBC
08.30-10.00 – Focus Session 8: Individualized therapy in major inflammatory skin diseases
Chairs: Jan Gutermuth (Belgium) & Ronald Vender (Canada)
1. Treat to target - Alexander Nast (Germany)
2. Transitioning between biologics - Ronald Vender (Canada)
3. Combination therapy - Pablo Coto (Spain)
4. Therapeutic drug monitoring in biologics - Ann Gils (Belgium)
FREE COMMUNICATIONS:
P014
IDENTIFICATION OF CLINICAL AND BIOMARKER PARAMETERS ASSOCIATED WITH LONG-TERM MAINTENANCE OF PASI 90 RESPONSE FOLLOWING GUSELKUMAB TREATMENT WITHDRAWAL IN PSORIASIS
X.Liu *, P.Branigan , Y.Chen , B.Scott , M.Banaszewska , P.McGovern , Z.Yao , S.Li , Y.Wasfi , M.Song , K.Campbell , E. J.Muñoz-Elías (Spring House, United States)
P015
DEFINING A MINIMAL EFFECTIVE SERUM TROUGH CONCENTRATION OF SECUKINUMAB IN PSORIASIS: A STEP TOWARDS PERSONALIZED THERAPY
R.Soenen , E.Meulewaeter , L.Grine , N.Van den Berghe , B.Els , R.Speeckaert , S.Lanssens , L.Temmerman , J.Lambert *, A.Gils (Ghent, Belgium)
10.30-12.30 – Plenary 3: Outcomes in psoriasis
Chairs: Jo Lambert (Belgium) & Ulrich Mrowietz (Germany)
1. Intro to value based healthcare, applied to a chronic disease model - Jan Gutermuth (Belgium)
2. Patient relevant outcome measures in psoriasis (IDEOM) - Alice Gottlieb (US)
3. Measures to treat psoriasis beyond drugs - Ulrich Mrowietz (Germany)
4. Can we justify the cost of a value based psoriasis approach? - Matthias Augustin (Germany)
12.30-14.00 Lunch break / Satellite Symposia
14.00-15.30 – Focus Session 9: Empowering HCPs in leadership and management
Chair: Jo Lambert (Belgium)
1. How to use resources effectively? - Jo Lambert (Belgium)
2. How to organise multidisciplinary teams? - Speaker TBC
3. How to deal with non-adherence in patients? - Speaker TBC
4. Shared decision making in chronic illnesses - Phyllis Spuls (Netherlands)
FREE COMMUNICATIONS:
P016
PLAQUE PSORIASIS IN HARD-TO-TREAT BODY LOCATIONS: CLINICAL MANAGEMENT AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS TREATED WITH BIOLOGIC AGENTS
W.Gulliver *, S.Gulliver , M.DiBattista , A.Kavanagh , S.Randell , R.Power , N.Gladney , H.Wang , D.MacDonald , S.Montmayeur , R.Burge (St. John's, Canada)
14.00-15.30 – Focus Session 10: Special situations: children, pregnancy, old age, cancer patients in major inflammatory skin diseases
Chairs: Isabel Belinchon (Spain) & Hugo Schönenberger de Oliveira (Portugal)
1. Pediatric patients with severe major inflammatory skin diseases - Speaker TBC
2. Paradoxical reactions - Speaker TBC
3. Scalp and genital psoriasis - Maria Lorna Frez (Philippines)
4. Old age/cancer patients - Satish Lubeek (Netherlands)
FREE COMMUNICATIONS:
P017
CO-EXISTENCE OF PSORIASIS AND ATOPIC DERMATITIS IN SAME PATIENTS AND FAMILIES
R.konathan *, B. S.papisetty , S. K.alur (Hyderabad, India)
P018
BIPE (BIOLOGICAL TREATMENTS FOR PPAEDIATRIC PSORIASIS) (BIPE):
A RETROSPECTIVE OBSERVATIONAL STUDY ON BIOLOGICAL DRUG SURVIVAL
IN DAILY PRACTICE IN CHILDHOOD PSORIASIS
C.Phan *, A.Beauchet , A. C.Bursztejn , S.Barbarot , C.Girard , A.Lasek , S.Hadj-Rabia , C.Abasq , C.Droitcourt , S.Mallet , A.Phan , J.-P.Lacour , E.Bourrat , G.Chaby , P.Plantin , A.Maruani , M.Piram , F.Maccari , A. C.Fougerousse , H.Barthélémy , L.Martin , L.Mery-Bossard , V.Pallure , D.Lons-Danic , E.Puzenat , M.Beylot-Barry , D.Bouilly-Auvray , F.Aubin , E.Mahé et the Groupe de Recherche de la Société Française de Dermatologie Pédiatrique, and the Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie (Argenteuil, France)
16.00-17.45 - Plenary 4: Medical need and Challenges in other Inflammatory Dermatoses
17.45-18.00 Closing remarks